Allergy Therapeutics PLC (LSE:AGY)

£ 0.034 0.0015 (4.62%) Market Cap: 162.06 Mil Enterprise Value: 158.39 Mil PE Ratio: 0 PB Ratio: 5.67 GF Score: 0/100

Full Year 2022 Allergy Therapeutics PLC Earnings Call Transcript
Sep 29, 2022

£0.19 (+2.70%)

Earnings
Q2 2022 Allergy Therapeutics PLC Earnings Call Transcript
Mar 10, 2022

£0.23 (+4.55%)

Earnings
Q4 2021 Allergy Therapeutics PLC Earnings Call Transcript
Mar 03, 2022

£0.2125

Earnings
Preliminary Full Year 2021 Allergy Therapeutics PLC Earnings Call Transcript
Sep 23, 2021

£0.385 (+2.39%)

Earnings
Allergy Therapeutics PLC VLP Peanut - a Next Generation Peanut Allergy Immunotherapy Call Transcript
Sep 17, 2021
Half Year 2021 Allergy Therapeutics PLC Earnings Call Transcript
Mar 03, 2021

£0.205 (-2.38%)

Earnings
Allergy Therapeutics PLC Annual Shareholders Meeting Transcript
Dec 08, 2020
Allergy Therapeutics plc - Special Call Transcript
Sep 23, 2020
Half Year 2020 Allergy Therapeutics PLC Earnings Call Transcript
Mar 04, 2020

£0.1075

Earnings
Full Year 2019 Allergy Therapeutics PLC Earnings Call Transcript
Sep 25, 2019

£0.132 (+1.54%)

Earnings

Q2 2022 Allergy Therapeutics PLC Earnings Call Transcript

Mar 10, 2022 / 10:30AM GMT

Release Date Price: £0.23 (+4.55%)

Transcript

Operator

Good day, ladies and gentlemen, and welcome to the Allergy Therapeutics interim results. (Operator Instructions) I would like to remind all participants that this call is being recorded.

And now let me hand it over to the CEO of Allergy Therapeutics, Manuel Llobet, to open the presentation. Please go ahead.

Manuel Llobet

Allergy Therapeutics plc - CEO & Executive Director

Thank you very much, and good morning, everyone, and many thanks for joining us today for Allergy Therapeutics Interim Results for the 6 months ended December 2021.

Joining me today are 2 people that you know well, Nick Wykeman, Allergy's Chief Financial Officer; and Alan Bullimore, our Head of Business Innovation.

As you can see here in this slide, maintaining focus for a pivotal year ahead, this is really a pivotal year. It has taken us a lot of effort, investment, energy and passion to reach this year where 2 pivotal studies that can be transformational for the company are taking place. We will give you more details of these studies during the presentation.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.